Map Pharma maps next moves after FDA denied migraine drug; Pacira raising $58.5M in offering;

@FierceBiotech: Amazon hungers for genomics data after NIH pact. Story | Follow @FierceBiotech

@JohnCFierce: Another PhRMA fact from Dow Jones: 3,200 trials under way versus 2,400 in 2005. More | Follow @JohnCFierce

@RyanMFierce: AstraZeneca's Brennan says investors' calls for change have no impact on his standing. Anyone smell blood in the water? More | Follow @RyanMFierce

> Map Pharmaceuticals ($MAPP) updated investors on its plans to talk to U.S. regulators after the FDA issued a complete response to the Mountain View, CA-based company's application for approval for a migraine drug called Levadex. Release

> Pacira Pharmaceuticals ($PCRX) plans to sell 6 million shares of stock in a public offering that is expected to bring in about $58.5 million. Item

> Australian biotech ImmunAid raised AU$1 million in a first-round financing. The company is working on improving treatments with its research of the immune system. Release

Pharma News

@FiercePharma: Lilly chief: We can't cut our way out of this mess. Need new drugs, new sales, too--Bloomberg. Article | Follow @FiercePharma

> Novartis reports patient taking Gilenya developed rare brain disease. Article

> Bloomberg: Bayer to pay $110 million to get out from under 500 Yaz lawsuits. Story

> Merck's Propecia and Proscar linked to sexual dysfunction. More

Medical Devices News

 @FierceMedDev: Firewall Created to safeguard against medical-device hacking | Imperial Valley News. News | Follow @FierceMedDev

> Purdue/Princeton team creates firewall for medical devices. Story

> Tornier to consolidate facilities in Europe, U.S. More

> What can St. Jude expect post-Riata? Article

> NeuroLogica, Stryker enter BodyTom pact. News

And Finally… Alexza Pharmaceuticals ($ALXA) faces a major moment with the FDA, which is expected to take action on the company's bid for approval of Adasuve for patients with bipolar disorder and schizophrenia by May 4. Article